Affymax (AFFY +4.9%) gains after announcing the FDA will review the company's application for...

|By:, SA News Editor

Affymax (AFFY +4.9%) gains after announcing the FDA will review the company's application for its Peginesatide drug, which treats anemia in patients with chronic kidney disease, on December 7, and has established an "action date" for the application of March 27.